Never in their wildest dreams dreams would immunologists from the last generation have imagined chimeric antigen receptor (CAR)-T cell therapy coming to light. The very notion of genetically engineering a T cell to recognize a tumor antigen would have been viewed almost as a pipe dream.
Nutritional change may be a potential strategy to improve symptom burden and inflammation in patients with MPNs, whohave increased inflammatory cytokines, which contribute to symptoms such as fatigue, night sweats and bone pain, as well as low cholesterol and weight loss related to nutritional deficiencies.
A retired oncologist and survivor talks cancer in a digital world.
Survey finds quality of life and cost affect treatment decisions.
Experts focus on genetic abnormalities to advance cancer care.
FOR THE FIRST TIME in more than 40 years, patients with acute myeloid leukemia (AML) have reason to hope. After years of little to no improvement, four new agents were approved in the same year bringing huge advancements to the field.
Experts examine the use of Adcetris for patients with Hodgkin lymphoma.
New drugs bring advancements to acute myeloid leukemia after 40 years.
Newly approved CAR-T cell treatments inspire hope in patients with blood cancer.
